The stock of PAVmed Inc. (NASDAQ:PAVM) decreased by -$0.02 on Tuesday to $0.31, down -6.23 percent. The last five days have seen an average of 523,182 shares of common stock traded. 6 times new highs were reached in the current year, with a fall of -$0.1691. The average number of shares traded over the last 20 days was 374,841, while the average volume over the last 50 days totaled 441,792.
PAVM stock dropped -21.57% since last month. On 08/11/23, the company’s shares reached a one-month low of $0.2875. The stock touched a high of $2.30 on 01/17/23, after rallying from a low of $0.29 in 52 weeks. The price of PAVM stock has declined by -36.29% or -$0.1691 this year, reaching a new high 6 times. Still, the stock price is down -86.70% from the 52-week high.
Insider Transactions
PAVM stock investors should be aware that PAVmed Inc. (PAVM) stock had its last reported insider trading activity 251 days ago on Dec 07. On Dec 07, Director Glennon Michael J acquired 100,000 shares at $0.62 each. This transaction resulted in the insider spending $62,320. On Dec 06, Glennon Michael J added 88,000 shares at a price of US$0.64. After the transaction, the insider now owns 150,000 shares. Director Glennon Michael J had earlier bought 62,000 shares on Dec 05 for $0.69 a share. The transaction was completed for $42,606.
Financial Health
For the three months ended March 30, PAVmed Inc.’s current ratio was 1.10. Based on annual data, it had gross profit of -$3.24 million and revenue of $0.38 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. PAVM’s return on assets (ROA) during the last 12 months has been -131.80%. There was a -430.20% return on investment (ROI) in the past year.
Earnings Surprise
According to PAVmed Inc.’s quarterly financial report for the quarter that ended March 30. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $0.57 million, while revenues rose by 66.67% to $0.11 million. It was predicted that PAVmed Inc.’s quarterly earnings would be -$0.19, but it ended up being -$0.21, beating the consensus by 9.50%. EBITDA was -$19.67 million for the quarter. At the end of PAVmed Inc.’s most recent quarter ended March 30, its liabilities totaled 54.48 million, while its total debt was $49.5 million. Equity owned by shareholders amounts to $104.53 million.
Technical Picture
Here’s a quick look at PAVmed Inc.’s (PAVM) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 32.30%, suggesting the stock is Neutral, with a 61.78% historical volatility rate.
The stochastic %K and %D were 25.31% and 18.99% respectively, while the average true range (ATR) was 0.0300. Based on the 14-day stochastic reading of 21.41%, the RSI (14) reading is 34.53%. On the 9-day MACD Oscillator, the stock is at -0.0133, and the 14-day reading is at -0.0297.
Analyst Ratings
In its analyst report released on March 30, 2021, Cantor Fitzgerald began covering PAVmed Inc. (NASDAQ: PAVM). The stock was rated as an Overweight by the brokerage firm. Analysts have assigned PAVmed Inc. (PAVM) an Overweight rating. PAVM is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 3 others recommend it as a buy.
What is PAVM’s price target for the next 12 months?
The current consensus forecast for the stock is between $1.40 and $7.50, with a median target price of $1.50. In analyzing these forecasts, the average price target given by analysts for PAVmed Inc. (PAVM) is $2.98.
